ATNM — Actinium Pharmaceuticals, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1388320 ·
Last close
$0.84
Market Cap
$26.26M
52W High
$1.38
52W Low
$0.81
ADV30
96,267
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,903,000 | -5,522,000 | 45,438,000 | 42,132,000 | 43,134,000 |
| Dec 2025 | 0 | — | -6,414,000 | -5,940,000 | 51,775,000 | 47,998,000 | 43,941,000 |
| Sep 2025 | 90,000 | — | -5,692,000 | -5,131,000 | 56,151,000 | 53,391,000 | 42,367,000 |
| Jun 2025 | 0 | — | -7,503,000 | -6,878,000 | 63,017,000 | 59,928,000 | 44,004,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-24,580,000
Investing CF
$-104,000
Financing CF
$-217,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.26
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-409,713,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-36,247,000
Pretax Income TTM
$-33,887,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$90,000
EBITDA
$-25,347,000
Free Cash Flow
$-14,791,000
Enterprise Value
$-14,355,270
Total Cash
$42,132,000
Total Debt
$1,519,000
Shares Out
31,374,994
Trailing EPS
$-0.76
Book Value
$0.07
ROE
-167.7%
ROA
-28.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 90,000 | -36,247,000 | -33,887,000 | 51,775,000 | 43,941,000 | — | -24,580,000 |
| Dec 2024 | 0 | -42,121,000 | -38,243,000 | 76,899,000 | 44,141,000 | — | -33,072,000 |
| Dec 2023 | 81,000 | -51,920,000 | -48,818,000 | 81,445,000 | 45,066,000 | — | -47,335,000 |
| Dec 2022 | 1,030,000 | -34,104,000 | -33,017,000 | 114,192,000 | 47,711,000 | — | 8,644,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.35
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABVC | ABVC BIOPHARMA, INC. | $26.26M | $1.01 | — |
| IGC | IGC Pharma, Inc. | $26.09M | $0.25 | — |
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | $26.48M | $0.06 | — |
| ACTU | ACTUATE THERAPEUTICS, INC. | $26.56M | $1.11 | — |
| QUCY | Quantum Cyber N.V. | $25.95M | $1.14 | — |
News headlines (Yahoo Finance, 1h cache)
Hematopoietic Stem Cell Transplantation Market Landscape to Evolve at a CAGR of 12.4% During the Forecast Period (2026-2036) as Novel Therapies and Expanding Patient Eligibility Drive Growth | DelveIn
2026-06-22 14:31 · Yahoo
Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
2026-06-03 12:00 · Yahoo
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros
2026-06-03 11:25 · Yahoo
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
2026-06-01 12:00 · Yahoo
Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates
2026-06-01 11:00 · Yahoo
Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
2026-05-29 21:31 · Yahoo
Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice
2026-05-29 21:30 · Yahoo
Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization
2026-05-06 12:00 · Yahoo
Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting
2026-04-22 11:00 · Yahoo
Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer
2026-04-22 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.